TABLE 2

Pharmacokinetic parameters for GLP-1 and GIP (intact and metabolites) during and after intravenous infusion in patients with renal insufficiency and control subjects

ParameterHealthy control subjectsPatients with CRISignificance (P value)*
Intact GLP-1 (7–36 amide)
  Area under the curve (pmol · l−1 · min)584 ± 97648 ± 1100.67
  Metabolic clearance rates (l/min)2.42 ± 0.452.35 ± 0.540.92
  t1/2 (min)2.3 ± 0.43.4 ± 0.60.13
  Distribution volume (l)7.1 ± 1.812.6 ± 4.60.28
GLP-1 metabolite (9–36 amide)
  Area under the curve (pmol · l−1 · min)2,287 ± 2935,203 ± 7760.0019
  Metabolic clearance rates (l/min)0.64 ± 0.160.25 ± 0.040.041
  t1/2 (min)3.3 ± 0.45.3 ± 0.80.029
  Distribution volume (l)2.7 ± 0.41.9 ± 0.30.12
Intact GIP (1–42)
  Area under the curve (pmol · l−1 · min)1,200 ± 3581,003 ± 1770.63
  Metabolic clearance rates (l/min)3.18 ± 0.622.02 ± 0.580.77
  t1/2 (min)5.0 ± 1.26.9 ± 1.40.31
  Distribution volume (l)17.4 ± 4.415.9 ± 3.80.80
GIP metabolite (3–42)
  Area under the curve (pmol · l−1 · min)1,847 ± 3112,965 ± 3560.031
  Metabolic clearance rates (l/min)1.56 ± 0.270.93 ± 0.210.088
  t1/2 (min)22.4 ± 3.038.1 ± 6.00.032
  Distribution volume (l)48.3 ± 9.357.0 ± 20.80.71
  • Data are means ± SE.

  • *

    * ANOVA.